加载中
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
常规交易时段
US$9.13
−US$0.18 · -1.93%
盘中时间采用ET。市场数据可能有所延迟。
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
日内区间
当前US$9.13
52周区间
当前US$9.13
盘中时间采用ET。市场数据可能有所延迟。
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
日内区间
当前US$9.13
52周区间
当前US$9.13
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 4847.1万 USD | 1.15亿 USD | — | — | — |
| 销货成本 | 100.2万 USD | — | — | — | — |
| 毛利 | 4746.9万 USD | 1.15亿 USD | — | — | — |
| 研究与开发 | 1.74亿 USD | 1.38亿 USD | 1.35亿 USD | 1.71亿 USD | 1.7亿 USD |
| 销售、一般及管理费用 | 3763.1万 USD | 3613.3万 USD | 3845.5万 USD | 4760.9万 USD | 4578.2万 USD |
| 营业费用 | 2.11亿 USD | 1.75亿 USD | 1.84亿 USD | 2.19亿 USD | 2.16亿 USD |
| 利息收入 | 197万 USD | 177.9万 USD | 199.7万 USD | 158.3万 USD | 76.1万 USD |
| 利息支出 | 1098.9万 USD | 1151.7万 USD | 1351.1万 USD | 1388万 USD | 1944万 USD |
| 折旧和摊销 | 100.2万 USD | 415.1万 USD | 438.5万 USD | 442.9万 USD | 516.7万 USD |
| 营业利润 | −1.63亿 USD | −5991.9万 USD | −1.84亿 USD | −2.19亿 USD | −2.16亿 USD |
| 净利润 | −1.7亿 USD | −5652.8万 USD | −1.8亿 USD | −2.29亿 USD | −2.34亿 USD |
公司数据更新于 2026年10月12日。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.47
下跌空间 61.99%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI117.49万0.00%2.3万亿 USD0.03%US$381.62-0.09%
iShares Biotechnology ETFIBB40.55万0.00%108.2亿 USD0.44%US$204.25-1.08%
Vanguard Extended Market ETFVXF38.14万0.00%954亿 USD0.05%US$234.2-0.34%
Vanguard Health Care ETFVHT22.42万0.00%220亿 USD0.09%US$319.58+0.18%
Invesco RAFI US 1500 Small-Mid ETFPRFZ11.7万0.00%26.7亿 USD0.36%US$52.985-0.33%
Eventide Small Cap ETFESSC2.97万0.09%3500万 USD0.49%US$28.65-0.38%
Invesco Nasdaq Biotechnology ETFIBBQ4059.160.00%1.12亿 USD0.19%US$34.245-1.08%
ProShares Ultra Nasdaq BiotechnologyBIB2187.850.00%9320.36万 USD1.19%US$108.8-1.96%Vanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEventide Small Cap ETFESSCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
